A Phase 1/2 study of ontorpacept (TTI-621) in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma

Sujana Movva, Victoria Allgood, Rashmi Chugh, Lara E. Davis, Howard H. Bailey, Mohammed Milhem, Varun Monga, Steven Attia, Ankit Mangla, Ingmar Bruns, Luke Kuttschreuter, Dalila Bouyoucef-Cherchalli, Caimiao Wei, Gloria H. Y. Lin, Hong Zhang, Ilan Pomerance, Mihaela Druta, Sant Chawla

Open source

DOI: 10.1038/s41416-026-03574-z
Published: 2026-08-04
Container: British Journal of Cancer
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41416-026-03574-z,
  title = {A Phase 1/2 study of ontorpacept (TTI-621) in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma},
  author = {Sujana Movva and Victoria Allgood and Rashmi Chugh and Lara E. Davis and Howard H. Bailey and Mohammed Milhem and Varun Monga and Steven Attia and Ankit Mangla and Ingmar Bruns and Luke Kuttschreuter and Dalila Bouyoucef-Cherchalli and Caimiao Wei and Gloria H. Y. Lin and Hong Zhang and Ilan Pomerance and Mihaela Druta and Sant Chawla},
  year = {2026},
  journal = {British Journal of Cancer},
  doi = {10.1038/s41416-026-03574-z},
  url = {https://doi.org/10.1038/s41416-026-03574-z}
}

RIS

TY  - JOUR
TI  - A Phase 1/2 study of ontorpacept (TTI-621) in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma
AU  - Sujana Movva
AU  - Victoria Allgood
AU  - Rashmi Chugh
AU  - Lara E. Davis
AU  - Howard H. Bailey
AU  - Mohammed Milhem
AU  - Varun Monga
AU  - Steven Attia
AU  - Ankit Mangla
AU  - Ingmar Bruns
AU  - Luke Kuttschreuter
AU  - Dalila Bouyoucef-Cherchalli
AU  - Caimiao Wei
AU  - Gloria H. Y. Lin
AU  - Hong Zhang
AU  - Ilan Pomerance
AU  - Mihaela Druta
AU  - Sant Chawla
PY  - 2026
JO  - British Journal of Cancer
DO  - 10.1038/s41416-026-03574-z
UR  - https://doi.org/10.1038/s41416-026-03574-z
ER  -

APA

Movva, S., Allgood, V., Chugh, R., Davis, L. E., Bailey, H. H., Milhem, M., Monga, V., Attia, S., Mangla, A., Bruns, I., Kuttschreuter, L., Bouyoucef-Cherchalli, D., Wei, C., Lin, G. H. Y., Zhang, H., Pomerance, I., Druta, M., & Chawla, S. (2026). A Phase 1/2 study of ontorpacept (TTI-621) in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03574-z

Source records

crossref · retrieved 2026-11-07T23:45:16.201Z